Disease Burden, Patient Experiences, and Unmet Needs in Those With Rheumatoid Arthritis Initiating a Third Advanced Therapy: Insights From 20 Years of Real‐World Data
ACR Open Rheumatology · 2026-02 · 8 (2)
DOI: 10.1002/acr2.70180 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 11.02.2026. Verfasst von Kristin Wipfler und 7 weiteren Autor:innen. Beteiligte Einrichtung: FORWARD, The National Databank for Rheumatic Diseases, Wichita, Kansas. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson & Johnson Innovative Medicine.
Abstract (Originalsprache)
Objective
Despite advances in rheumatoid arthritis (RA) treatment, a considerable proportion of patients exhibit refractory disease, prompting the need for a comprehensive understanding of refractory RA. We aimed to analyze the burden and patient experiences associated with initiation of a third biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) (BT3‐RA) in a large observational cohort.
Methods
Data were obtained from participants with RA in the FORWARD Databank from 1999 to 2019. Participants, stratified into BT3‐RA and a comparator BT1‐RA (first initiation of a b/tsDMARD) cohorts, were matched based on key demographic and disease‐specific parameters. Demographics, patient‐reported outcomes (PROs), comorbidities, and health care interactions were assessed at initiation of first advanced therapy and at the time of meeting BT3‐RA criteria.
Results
After matching, 1,384 participants were included in the study (692 each for BT3‐RA and BT1‐RA). The BT3‐RA cohort had worse PROs, greater comorbidity burden, and lower health satisfaction than BT1‐RA controls. Those with BT3‐RA had significantly higher odds of having a greater number of rheumatology visits in the previous six months than controls (>4 visits, 0–2 visit reference, odd ratio [OR] 3.8 [95% confidence interval (CI) 2.7–5.4], P < 0.001; 3–4 visits, 0–2 visit reference, OR 1.9 [95% CI 1.5–2.5]; P < 0.001). Those with BT3‐RA also had higher odds of concomitant glucocorticoid use (OR 1.5 [95% CI 1.2–2.0], P < 0.001) and gastrointestinal disorders (OR 1.5 [95% CI 1.1–1.9], P < 0.01).
Conclusion
Exposure to three advanced RA therapies was associated with significant disease burden and unmet health care needs. These findings underscore the importance of well‐defined refractory criteria and the need for further investigation into this RA phenotype to identify targeted treatment strategies and ultimately improve outcomes. image
Autor:innen und Institutionen
- FORWARD, The National Databank for Rheumatic Diseases, Wichita, Kansas.
- University of Washington, Seattle, Washington.
- Johnson & Johnson Innovative Medicine, Raritan, New Jersey.
- University of California San Francisco, San Francisco, California.
- University of Nebraska Medical Center, Omaha, Nebraska.
ORCID-Profile: Kristin Wipfler, Anna Sheahan, Patti Katz, Kaleb Michaud
Förderung
- Johnson & Johnson Innovative Medicine
Zitieren
APA
Wipfler, K., Pedro, S., Han, B. K., Sbarigia, U., Zazzetti, F., Sheahan, A., Katz, P., & Michaud, K. (2026). Disease Burden, Patient Experiences, and Unmet Needs in Those With Rheumatoid Arthritis Initiating a Third Advanced Therapy: Insights From 20 Years of Real‐World Data. ACR Open Rheumatology, 8(2). https://doi.org/10.1002/acr2.70180
Vancouver
Wipfler K, Pedro S, Han BK, Sbarigia U, Zazzetti F, Sheahan A, et al. Disease Burden, Patient Experiences, and Unmet Needs in Those With Rheumatoid Arthritis Initiating a Third Advanced Therapy: Insights From 20 Years of Real‐World Data. ACR Open Rheumatology. 2026;8(2). doi:10.1002/acr2.70180
BibTeX
@article{Wipfler2026,
author = {Wipfler, Kristin and Pedro, Sofia and Han, Bobby Kwanghoon and Sbarigia, Urbano and Zazzetti, Federico and Sheahan, Anna and Katz, Patti and Michaud, Kaleb},
title = {Disease Burden, Patient Experiences, and Unmet Needs in Those With Rheumatoid Arthritis Initiating a Third Advanced Therapy: Insights From 20 Years of Real‐World Data},
journal = {ACR Open Rheumatology},
year = {2026},
volume = {8},
number = {2},
doi = {10.1002/acr2.70180}
}
EUVIMED